Paper Details

  1. Home
  2. Paper Details

Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans.

Author: FiorucciStefano, LechiAlessandro, MencarelliAndrea, MeneguzziAlessandra, MinuzPietro, MorelliAntonio, RengaBarbara, del SoldatoPiero

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

NCX-4016, an aspirin derivative, was found to be equally effective as aspirin in inhibiting platelet aggregation and cyclooxygenase activity. However, NCX-4016 caused less gastric damage and prevented monocyte activation, suggesting broader anti-inflammatory and antithrombotic effects. Larger multicenter trials are needed to establish clinical efficacy and safety.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: The goal of this study was to test the hypothesis that NCX-4016 may have broader anti-inflammatory and antithrombotic effects as well as better gastric tolerability than aspirin in humans. BACKGROUND: NCX-4016 is an aspirin derivative containing a nitric oxide-releasing moiety that prev...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15358033

データ提供：米国国立医学図書館（NLM）

Co-administration of Nitric Oxide-Aspirin and Aspirin for Cardiovascular Health

This study investigates the potential benefits of co-administering nitric oxide-aspirin (NCX-4016) and aspirin for cardiovascular health. Imagine a desert traveler seeking protection from the sun's intense rays, where a combination of sunscreen and a hat might offer greater protection than either alone. This research explores the synergistic effects of combining these two medications for preventing platelet activation and reducing gastric damage.

NCX-4016 Offers Additional Benefits Over Aspirin Alone

The study found that NCX-4016, an aspirin derivative that releases nitric oxide, provides similar benefits to aspirin in inhibiting platelet aggregation and reducing thromboxane production. However, NCX-4016 also offers additional advantages, including the ability to prevent monocyte activation and reduce gastric damage, especially when co-administered with aspirin. It's like adding a layer of protection, like a desert traveler wearing a hat and using sunscreen to shield themselves from the sun's harmful rays.

Potential for Improved Cardiovascular Care

This research highlights the potential of NCX-4016 as a promising new medication for improving cardiovascular health. It's like finding a new oasis in the desert, offering a more effective and well-tolerated approach to addressing cardiovascular risks. The study encourages further research to evaluate the clinical efficacy and safety of NCX-4016 for broader applications in cardiovascular care.

Dr. Camel's Conclusion

This study underscores the importance of exploring new and innovative approaches to cardiovascular health, emphasizing the potential of nitric oxide-releasing compounds like NCX-4016. It's a reminder that finding the right combination of strategies, like a desert traveler carefully selecting their gear and supplies, can lead to more effective and safer outcomes. The researchers have opened new avenues for research and development, offering hope for improved therapies and better cardiovascular health for individuals worldwide.
Date :
  1. Date Completed 2004-09-21
  2. Date Revised 2017-11-16
Further Info :

Pubmed ID

15358033

DOI: Digital Object Identifier

S0735109704010022

Related Literature

Article Analysis
・Effects of aspirin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.